Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Receivables (2016 - 2025)

Historic Receivables for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $297.7 million.

  • United Therapeutics' Receivables fell 1290.23% to $297.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.7 million, marking a year-over-year decrease of 1290.23%. This contributed to the annual value of $279.3 million for FY2024, which is 14.34% up from last year.
  • As of Q3 2025, United Therapeutics' Receivables stood at $297.7 million, which was down 1290.23% from $379.3 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Receivables ranged from a high of $379.3 million in Q2 2025 and a low of $134.5 million during Q1 2023
  • Over the past 5 years, United Therapeutics' median Receivables value was $258.6 million (recorded in 2023), while the average stood at $246.6 million.
  • As far as peak fluctuations go, United Therapeutics' Receivables tumbled by 2111.44% in 2023, and later surged by 12847.58% in 2024.
  • Over the past 5 years, United Therapeutics' Receivables (Quarter) stood at $198.7 million in 2021, then increased by 10.92% to $220.4 million in 2022, then rose by 26.54% to $278.9 million in 2023, then rose by 0.14% to $279.3 million in 2024, then rose by 6.59% to $297.7 million in 2025.
  • Its last three reported values are $297.7 million in Q3 2025, $379.3 million for Q2 2025, and $322.0 million during Q1 2025.